SCHEMBL4816347

SCHEMBL4816347

COC(=O)c1ccc(C#CCNC(=O)OC(C)(C)C)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 2/20 0.64
MAPT P10636 3/20 0.46
DDB1 Q16531 2/20 0.45
CRBN Q96SW2 2/20 0.45
ADRA2A P08913 1/20 0.44
DRD5 P21918 1/20 0.44
DRD3 P35462 1/20 0.44
P2RY6 Q15077 1/20 0.44
SOST Q9BQB4 1/20 0.43
RAB9A P51151 1/20 0.42
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
CA12 O43570 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7231271 0.87 PTPN11 (0.70) PTPN11MAPTDDB1CRBNADRA2A
SCHEMBL31747254 0.86 PTPN11 (0.64) PTPN11MAPTDDB1CRBNADRA2A
SCHEMBL5724842 0.84 DDB1 (0.54) PTPN11MAPTDDB1CRBNADRA2A
SCHEMBL31747289 0.84 DDB1 (0.54) PTPN11MAPTDDB1CRBNADRA2A
SCHEMBL3007876 0.84 NAMPT (0.49) PTPN11MAPTCA1CA2LOXL2
SCHEMBL11997705 0.83 PTPN11 (0.67) PTPN11DDB1CRBNADRA2ADRD5
SCHEMBL29691832 0.83 PTPN11 (0.67) PTPN11DDB1CRBNADRA2ADRD5
SCHEMBL25693853 0.83 PTPN11 (0.67) PTPN11DDB1CRBNADRA2ADRD5
SCHEMBL13290619 0.83 PTPN11 (0.67) PTPN11DDB1CRBNADRA2ADRD5
SCHEMBL21881992 0.82 PTPN11 (0.71) PTPN11DDB1CRBNADRA2ADRD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080248506-A1 Method of Monitoring Anti-Tumor Activity of an Hdac Inhibitor PHARMACYCLICS, INC. (US) 2008-10-09 US disclosed
US-20080139547-A1 ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE PHARMACYCLICS, INC. (US) 2008-06-12 US disclosed
US-7368572-B2 Acetylene derivatives as inhibitors of histone deacetylase PHARMACYCLICS, INC. (US) 2008-05-06 US disclosed
US-20070105939-A1 Mesylate salt of 5-(2-dimethylaminoethoxy)-1H-indole-2-carboxylic acid [3-(4-hydroxycarbamoylphenyl)prop-2-ynyl]amide PHARMACYCLICS, INC. (US) 2007-05-10 US disclosed
US-20070105939-A1 Mesylate salt of 5-(2-dimethylaminoethoxy)-1H-indole-2-carboxylic acid [3-(4-hydroxycarbamoylphenyl)prop-2-ynyl]amide PHARMACYCLICS, INC. (US) 2007-05-10 US disclosed
EP-1656348-B1 ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE AXYS PHARM INC (US) 2007-02-07 EP disclosed
US-20050131018-A1 Acetylene derivatives as inhibitors of histone deacetylase AXYS PHARMACEUTICALS, INC. (US) 2005-06-16 US disclosed
US-20030153604-A1 Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds AVENTIS PHARMACEUTICALS INC. 2003-08-14 US disclosed
US-6541505-B1 Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. AVENTIS PHARMACEUTICALS INC. 2003-04-01 US disclosed
EP-1140901-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS Aventis Pharmaceuticals Products Inc. (US) 2001-10-10 EP disclosed
WO-2000039087-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139547-A1 ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE HDAC1, HDAC10, HDAC2 PTPN11 4788/4885MAPT 2799/4885DDB1 1707/4885
US-20070105939-A1 Mesylate salt of 5-(2-dimethylaminoethoxy)-1H-indole-2-carboxylic acid [3-(4-hydroxycarbamoylphenyl)prop-2-ynyl]amide HTR5A, HTR2B, HTR2A PTPN11 1720/4885MAPT 1362/4885DDB1 4494/4885
US-20050131018-A1 Acetylene derivatives as inhibitors of histone deacetylase HDAC1, HDAC10, HDAC2 PTPN11 4788/4885MAPT 2799/4885DDB1 1707/4885
US-20030153604-A1 Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds SERPINC1, F2, F11 PTPN11 2894/4885MAPT 4540/4885DDB1 3023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.